In his letter discussing the article by Kupersmith et al1 on corticosteroid treatment for ocular myasthenia gravis, McQuillen2 emphasizes that Kupersmith et al "neglected to mention the only controlled clinical trial of anything in myasthenia—namely of corticotropin" citing the article by Mount.3 For the record, there have been other controlled trials of therapy in myasthenia gravis. In 1976 Howard et al4 from the Mayo Clinic, Rochester, Minn, reported, "Alternate-day prednisone: preliminary report of a double-blind controlled study" in which prednisone, 100 mg alternate day, was given to patients with moderately severe myasthenia gravis. Thirteen patients were followed up for 6 months. Six of the patients were receiving prednisone, 3 of whom improved. Seven patients were receiving placebo, of whom "three were improved and had minimal disability well controlled by small amounts of anticholinesterase medication." The authors3 further state that "finally, any evaluation of treatment of
Pascuzzi RM. Controlled Clinical Trials of Anything in Myasthenia Gravis. Arch Neurol. 1997;54(11):1323. doi:10.1001/archneur.1997.00550230006003
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: